Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/84—Nitriles
  • C07D213/85—Nitriles in position 3
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
  • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/56—Nitrogen atoms
  • C07D211/58—Nitrogen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/73—Unsubstituted amino or imino radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/84—Nitriles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
  • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
  • C07D235/26—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D277/24—Radicals substituted by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
  • C07D295/28—Nitrogen atoms
  • C07D295/30—Nitrogen atoms non-acylated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This invention pertains to compounds which inhibit the activity of Bcl-2
• anti-apoptotic proteins compositions containing the compounds, and methods of treating diseases during which anti-apoptotic Bcl-2 proteins are expressed.
• Anti-apoptotic Bcl-2 proteins are associated with a number of diseases. There is therefore an existing need in the therapeutic arts for compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins.
• Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system.
• Bcl-2 proteins in bladder cancer brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/37911, published as WO 2005/024636.
• a 1 is N or C(A 2 );
• a 2 is H, R 1 , OR 1 , SR 1 , NHR 1 , NCR 1 )!, C(0)NHR 1 , CCCONCR 1 )!, NHC(0)R 1 , NR ⁇ COJR 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 ,
• B 1 is H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R 1 , C(0)OR ⁇ OC(0)R ⁇ NHR 1 , N(R ] ) 2 , NHC(0)OR 1 , NR 1 C(0)OR 1 ,
• D 1 is H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇ C(0)OR ⁇ 0C(0)R 1 , NHR 1 , NCR 1 )!, C(0)NHR ⁇ C(0)N(R 1 ) 2 , NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR ⁇ NR 1 C(0)0R 1 ,
• E 1 is H, R 1 , OR 1 , SR 1 , C(0)0R 1 , 0C(0)R 1 , NHR 1 , N(R ] ) 2 , C(0)N(R 1 ) 2 , NHC(0)R 1 , NR 1 C(0)R 1 , NR 1 C(0)0R 1 ,
• Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 ,
• E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• a 2 , B 1 , and D 1 are independently selected H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R 1 , C(0)OR ⁇ OC(0)R ⁇ NHR 1 , N(R ] ) 2 , C(0)NHR ⁇ C ⁇ NCR 1 ) ⁇ NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , C(NH)NHR ⁇ C(NH)N(R') 2 NHS0 2 NHR ⁇ NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
• Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• a 2 , D 1 , and E 1 are independently selected H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇ NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR ⁇ NCR ⁇ z, S0 2 NH 2 , S0 2 NHR ⁇ SOzNCR 1 ⁇ , NHS0 2 R ⁇ NR ⁇ OzR 1 , NHS0 2 NHR ⁇ NHSOzNCR ⁇ z, NR ⁇ OzNHR 1 , NR ⁇ OzNCR 1 ⁇ , C(0)NHNOH, C(0)NHNOR 1 ,
• a 2 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• D 1 , E 1 , and Y 1 are independently selected H, R 1 , OR 1 , SR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
• a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• B 1 , E 1 , and Y 1 are independently selected H, R 1 , OR 1 , SR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , C(NH)NHR ⁇ QNHJNiR ⁇ NHS0 2 NHR ⁇ NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
• R 1 is R 2 , R 3 , R 4 or R 5 ;
• R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
• 2 is phenyl, which is unfused or fused with benzene, heteroarene or 2A 2A R R ;
• R is cycloalkane or heterocycloalkane;
• R 3 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 3A ;
• R 3A is cycloalkane or heterocycloalkane;
• R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 4A ;
• R 4A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , NHC(0)NH 2 , NHC(0)NHR 7 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 1 , OH, (O), C(0)OH
• R 6 is C 2 -C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N 3 , CN, CF 3 , CF 2 CF 3 , F, CI, Br, I, NH 2 , NH(CH 3 ) or N(CH 3 ) 2 ;
• R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
• R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
• R 7 is R 8 , R 9 , R 10 or R n ;
• R 8 is phenyl, which is unfused or fused with benzene, heteroarene or R 8A ;
• R 8A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 9 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 9A ;
• R 9A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 10A ;
• R 10A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 ,
• R 12 is R 13 , R 14 , R 15 or R 16 ;
• R 13 is phenyl, which is unfused or fused with benzene, heteroarene or R 13A ;
• R 13A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 14 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 14A ;
• R 14A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R 15A ;
• R 15A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 16 is alkyl, alkenyl or alkynyl
• R 17 is R 18 , R 19 , R 20 or R 21 ;
• R 18 is phenyl, which is unfused or fused with benzene, heteroarene or R 18A ;
• R 18A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 19 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 19A ;
• R 19A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 20A ;
• R 20A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 , NHS(0) 2 R 22 , NR 22 S(0) 2 R 22 , NHC(0)OR 22 , NR 22 C(0)OR 22 , NHC(0)NH 2 , NHC(0)NHR 22 , NHC(0)N(R 22 ) 2 , NR 22 C(0)NHR 22 , NR 22 C(0)N(R 22 ) 2 , C(0)NH 2 , C(0)NHR 22 , C(0)N(R 22 ) 2 , C(0)NHOH, C(0)NHOR 22 , C(0)NHS0 2 R
• R 22 is R 23 , R 24 or R 25 ;
• R 23 is phenyl, which is unfused or fused with benzene, heteroarene or R 23A ;
• R 23A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 24 is heteroarene, which is unfused or fused with benzene, heteroarene or R 24A ;
• R 24A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 25A ;
• R 25A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• Z 1 is R 26 or R 27 ;
• Z 2 is R 28 , R 29 or R 30 ;
• Z 1A and Z 2A are both absent or are taken together to form CH 2 , CH 2 CH 2 or Z 12A ;
• Z 12A is C 2 -C6-alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S, S(O) or S0 2 ;
• L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
• R 26 is phenylene, which is unfused or fused with benzene or heteroarene or R 26 ⁇ ;
• R 26 ⁇ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 27 is heteroarylene, which is unfused or fused with benzene or heteroarene or R 27A ;
• R 27 A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene
• R 28 is phenylene, which is unfused or fused with benzene, heteroarene or R 28A ;
• R 28A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 29 is heteroarylene, which is unfused or fused with benzene or heteroarene or R 29A ;
• R 29A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ;
• R 30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with benzene, heteroarene or R 30A ;
• R 30A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 37 is a bond or R 37A
• R 37A is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R 37B , S0 2 R 37B , C(0)R 37B , CO(0)R 37B , OC(0)R 37B , OC(0)OR 37B , NH 2 , NHR 37B , N(R 37B ) 2 , NHC(0)R 37B , NR 37B C(0)R 37B , NHS(0) 2 R 37B , NR 37B S(0) 2 R 37B , NHC(0)OR 37B ,
• NR 37B C(0)OR 37B NHC(0)NH 2 , NHC(0)NHR 37B , NHC(0)N(R 37B ) 2 , NR 37B C(0)NHR 37B , NR 37B C(0)N(R 37B ) 2 , C(0)NH 2 , C(0)NHR 37B , C(0)N(R 37B ) 2 , C(0)NHOH, C(0)NHOR 37B , C(0)NHS0 2 R 37B , C(0)NR 37B S0 2 R 37B , S0 2 NH 2 , S0 2 NHR 37B , S0 2 N(R 37B ) 2 , C(0)H, C(0)OH, C(N)NH 2 , C(N)NHR 37B , C(N)N(R 37B ) 2 , CNOH, CNOCH 3 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF3, OCF 2 CF 3 , F,
• R 37B is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;
• Z 3 is R 38 , R 39 or R 40 ;
• R 38 is phenyl, which is unfused or fused with benzene, heteroarene or R 38A ;
• R 38A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 39 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 39A ;
• R 39A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R >40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfusseedd oorr ffuusseedd wwiitthh bbeennzzeennee,, hheetteerrooaarene or R ;
• R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R and R are substituted (i.e., if Z and Z are absent) or further substituted (i.e., if Z 1A and Z 2A are present) with one or two or three or four of independently selected R 41 , OR 41 , SR 41 , S(0)R 41 , S0 2 R 41 , C(0)R 41 , CO(0)R 41 , OC(0)R 41 , OC(0)OR 41 , NH 2 , NHR 41 , N(R 41 ) 2 , NHC(0)R 41 , NR 41 C(0)R 41 , NHS(0) 2 R 41 , NR 41 S(0) 2 R 41 , NHC(0)OR 41 , NR 41 C(0)OR 41 , NHC(0)NH 2 , NHC(0)NHR 41 ,
• R is phenyl, which is unfused or fused with benzene, heteroarene or R ;
• R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 43 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 43A ;
• R 43A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 44 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 44A ;
• R 44A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 4t ⁇ 0R 4t ⁇ SR 4t ⁇ S(0)R 4t ⁇ S0 2 R , C(0)R , CO(0)R 46 , OC(0)R 46 , OC(0)OR 46 , NH 2 , NHR 46 , N(R 46 ) 2 , NHC(0)R 46 , NR 46 C(0)R 46 , NHS(0) 2 R 46 , NR 46 S(0) 2 R 46 , NHC(0)OR 46 , NR 46 C(0)OR 46 , NHC(0)NH 2 , NHC(0)NHR 46 , NHC(0)N(R 46 ) 2 , NR 46 C(0)NHR 46 , NR 46 C(0)N(R 46 ) 2 , C(0)NH 2 , C(0)NHR 46 , C(0)N(R 46 ) 2 , C(0)NHOH, C(0)NHOR 46 , C(0)NHS
• R 46 is alkyl, alkenyl, alkynyl, R 47 , R 48 or R 49 ;
• R 47 is phenyl, which is unfused or fused with benzene, heteroarene or R 47A ;
• R 47A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 48 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 48A ;
• R 48A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 49 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 49A ;
• R 49A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R , R , and R are independently substituted with one or two or three or four of independently selected R 50 , OR 50 , SR 50 , S(0)R 50 , S0 2 R 50 , C(0)R 50 , CO(0)R 5 °, OC(0)R 5 °, OC(0)OR 50 , NH 2 , NHR 50 , N(R 50 ) 2 , NHC(0)R 50 , NR 50 C(O)R 50 , NHS(0) 2 R 50 , NR 50 S(O) 2 R 50 , NHC(0)OR 50 , NR 50 C(O)OR 50 , NHC(0)NH 2 , NHC(0)NHR 50 , NHC(O)N(R 50 ) 2 ,
• C(0)NHOR 50 C(0)NHS0 2 R 50 , C(O)NR 50 SO 2 R 50 , S0 2 NH 2 , S0 2 NHR 50 , SO 2 N(R 50 ) 2 , C(0)H, C(0)OH, C(N)NH 2 , C(N)NHR 50 , C(N)N(R 50 ) 2 , CNOH, CNOCH3, OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF3, OCF 2 CF 3 , F, CI, Br or I;
• R is phenyl, which is unfused or fused with benzene, heteroarene or R ;
• R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 52 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 52A ;
• R 52A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 53 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 53A ;
• R 53A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 54 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 55 , OR 55 , SR 55 , S(0)R 55 , S0 2 R 55 , C(0)R 55 , CO(0)R 55 , OC(0)R 55 , OC(0)OR 55 , NH 2 , NHR 55 , N(R 55 ) 2 , NHC(0)R 55 , NR 55 C(0)R 55 ,
• R 55 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
• each foregoing cyclic moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R 57A , R 57 , OR 57 , SR 57 , S(0)R 57 , S0 2 R 57 , C(0)R 57 , CO(0)R 57 ,
• OC(0)R 57 , OC(0)OR 57 NH 2 , NHR 57 , N(R 57 ) 2 , NHC(0)R 57 , NR 57 C(0)R 57 , NHS(0) 2 R 57 , NR 57 S(0) 2 R 57 , NHC(0)OR 57 , NR 57 C(0)OR 57 , NHC(0)NH 2 , NHC(0)NHR 57 ,
• R 57A is spirocyclyl
• R 57 is R 58 , R 59 , R 60 or R 61 ;
• RR 58 i iss pphheennyyll,, wwhhiicchh iiss uunnifused or fused with benzene, heteroarene or R ;
• R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 59 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 3yA ;
• R 3yA is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 60A ;
• R 60A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 62 , OR 62 , SR 62 , S(0)R 62 , S0 2 R 62 , C(0)R 62 , CO(0)R 62 , OC(0)R 62 , OC(0)OR 62 , NH 2 , NHR 62 , N(R 62 ) 2 , NHC(0)R 62 , NR 62 C(0)R 62 , NHS(0) 2 R 62 , NR 62 S(0) 2 R 62 , NHC(0)OR 62 , NR 62 C(0)OR 62 , NHC(0)NH 2 , NHC(0)NHR 62 , NHC(0)N(R 62 ) 2 , NR 62 C(0)N(R 62 ) 2 , C(0)NH 2 , C(0)NHR 62 , C(0)N(R 62 ) 2 , C(0)
• R 62 is R 63 , R 64 , R 65 or R 66 ;
• R 63 is phenyl, which is unfused or fused with benzene, heteroarene or R 63A ;
• R 63A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 64 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 64A ;
• R 64A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 65 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 65A ;
• R 65A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 66 is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 67 , OR 67 , SR 67 , S(0)R 67 , S0 2 R 67 , C(0)R 67 , CO(0)R 67 , OC(0)R 67 , OC(0)OR 67 , NH 2 , NHR 67 , N(R 67 ) 2 , NHC(0)R 67 , NR 67 C(0)R 67 , NHS(0) 2 R 67 , NR 67 S(0) 2 R 67 , NHC(0)OR 67 , NR 67 C(0)OR 67 , NHC(0)NH 2 , NHC(0)NHR 67 , NHC(0)N(R 67 ) 2 , NR 67 C(0)NHR 67 , NR 67 C(0)N(R 67 ) 2 , C(0)NH 2 , C(0)NHR 67 , C(0)N
• RR 67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, pphhenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
• R , R , R 3y , R , R , R , R , and R b are unsubstituted or substituted with one or two or three or four of independently selected R 68 , OR 68 , SR 68 , S(0)R 68 , S0 2 R 68 , C(0)R 68 , CO(0)R 68 , OC(0)R 68 , OC(0)OR 68 , NH 2 , NHR 68 , N(R 68 ) 2 , NHC(0)R 68 , NR 68 C(0)R 68 , NHS(0) 2 R 68 , NR 68 S(0) 2 R 68 , NHC(0)OR 68 ,
• NR 68 C(0)OR 68 NHC(0)NH 2 , NHC(0)NHR 68 , NHC(0)N(R 68 ) 2 , NR 68 C(0)NHR 68 ,
• R 68 is R 69 , R 70 , R 71 or R 72 ;
• R 69 is phenyl, which is unfused or fused with benzene, heteroarene or R 69A ;
• R 69A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 70 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 70A ;
• R 70A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 71A ;
• R 71A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 72 is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 73 , OR 73 , SR 73 , S(0)R 73 , S0 2 R 73 , C(0)R 73 , CO(0)R 73 , OC(0)R 73 , OC(0)OR 73 , NH 2 , NHR 73 , N(R 73 ) 2 , NHC(0)R 73 , NR 73 C(0)R 73 ,
• R 73 is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
• the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH 2 , C(0)NH 2 , C(0)NHOH, S0 2 NH 2 , CF 3 , CF 2 CF 3 , C(0)H, C(0)OH, C(N)NH 2 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, CI, Br or I.
• Another embodiment pertains to a compound having Formula (II)
• R 100 is as described for substituents on R 26 ;
• n 0, 1, 2, or 3;
• R 101 is as described for substituents on R 42 ;
• n 1, 2, 3, 4, or 5;
• a 1 is N or C(A 2 );
• a 2 is H, R 1 , OR 1 , SR 1 , 0C(0)R 1 , NHR 1 , NCR 1 ) ! , NHC(0)0R 1 , NR 1 C(0)0R 1 ,
• B 1 is H, R 1 , OR 1 , SR 1 , NHR 1 , N(R ] ) 2 , C(0)NHR 1 , CCO R 1 ⁇ , NHC(0)R 1 , NR ⁇ COJR 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 ,
• D 1 is H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇ C(0)OR ⁇ OC(0)R ⁇ NHR 1 , NCR 1 ) ! , C(0)NHR 1 , C(0)N(R 1 ) 2 , NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 ,
• E 1 is H, R 1 , OR 1 , SR 1 ,
• Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 , C(0)R 17 , C(0)OR 17 , SR 17 , S0 2 R 17 , NH 2 , NHR 17 , N(R 17 ) 2 , NHC(0)R 17 , C(0)NH 2 ,
• E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• a 2 , B 1 , and D 1 are independently selected H, R 1 , OR 1 , SR 1 , C(0)R 1 , NHC(0)R 1 , NR 1 C(0)R 1 ,
• NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR ⁇ NCR ⁇ z, S0 2 NH 2 , S0 2 NHR ⁇ SOzNCR 1 ⁇ , NHS0 2 R ⁇ NR ⁇ OzR 1 , NHS0 2 NHR ⁇ NHSOzNCR ⁇ z, NR ⁇ OzNHR 1 , NR ⁇ OzNCR 1 ⁇ , C(0)NHNOH, C(0)NHNOR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
• Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• a 2 , D 1 , and E 1 are independently selected H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇ NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 ,
• a 2 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• D 1 , E 1 , and Y 1 are independently selected H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇ C(0)OR 1 , OC(0)R ⁇ NHR 1 , N(R ] ) 2 , C(0)NHR ⁇ C ⁇ NCR 1 ) ⁇ NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , C(NH)NHR ⁇ C(NH)N(R') 2 NHS0 2 NHR ⁇ NHS0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
• a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• B 1 , E 1 , and Y 1 are independently selected H, R 1 , OR 1 , SR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , C(NH)N(R') 2 NHSOZNHR 1 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
• R 1 is R 2 , R 3 , R 4 or R 5 ;
• R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
• R is phenyl, which is unfused or fused with benzene, heteroarene or R ;
• R is cycloalkane or heterocycloalkane;
• R 3 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 3A ;
• R 3A is cycloalkane or heterocycloalkane;
• R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 4A ;
• R 4A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , NHC(0)NH 2 , NHC(0)NHR 7 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 1 , OH, (O
• R 6 is C 2 -C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N 3 , CN, CF 3 , CF 2 CF 3 , F, CI, Br, I, NH 2 , NH(CH 3 ) or N(CH 3 ) 2 ;
• R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
• R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
• R 7 is R 8 , R 9 , R 10 or R n ;
• R 8 is phenyl, which is unfused or fused with benzene, heteroarene or R 8A ;
• R 8A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 9 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 9A ;
• R 9A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 10A ;
• R 10A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 , NHS(0) 2 R 12 , NR 12 S(0) 2 R 12 , NHC(0)OR 12 , NR 12 C(0)OR 12 , NHC(0)NH 2 , NHC(0)NHR 12 , NHC(0)N(R 12 ) 2 , NR 12 C(0)NHR 12 , NR 12 C(0)N(R 12 ) 2 , C(0)NH 2 , C(0)NHR 12 , C(0)N(R 12 ) 2 , C(0)NHOH, C(0)NHOR 12 , C(0)NHS0 2 R
• R 12 is R 13 , R 14 , R 15 or R 16 ;
• R 13 is phenyl, which is unfused or fused with benzene, heteroarene or R 13A ;
• R 13A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 14 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 14A ;
• R 14A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R 15A ;
• R 15A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 16 is alkyl, alkenyl or alkynyl
• R 17 is R 18 , R 19 , R 20 or R 21 ;
• R 18 is phenyl, which is unfused or fused with benzene, heteroarene or R 18A ;
• R 18A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 19 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 19A ;
• R 19A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 20A ;
• R 20A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 ,
• R 22 is R 23 , R 24 or R 25 ;
• R 23 is phenyl, which is unfused or fused with benzene, heteroarene or R 23A ;
• R 23A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 24 is heteroarene, which is unfused or fused with benzene, heteroarene or R 24A ;
• R 24A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 25A ;
• R 25A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• Z 2 is R 28 , R 29 or R 30 ;
• Z 1A and Z 2A are both absent or are taken together to form CH 2 , CH 2 CH 2 or Z 12A ;
• Z 12A is C 2 -C6-alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S,
• L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
• R 28 is phenylene, which is unfused or fused with benzene, heteroarene or R 28A ;
• R 28A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 29 is heteroarylene, which is unfused or fused with benzene or heteroarene or R 29A ;
• R 29A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ;
• R 30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with benzene, heteroarene or R 30A ;
• R 30A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 37 is a bond or R 37A
• R 37A is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R 37B , S0 2 R 37B , C(0)R 37B , CO(0)R 37B , OC(0)R 37B , OC(0)OR 37B , NH 2 , NHR 37B , N(R 37B ) 2 , NHC(0)R 37B , NR 37B C(0)R 37B , NHS(0) 2 R 37B , NR 37B S(0) 2 R 37B , NHC(0)OR 37B ,
• NR 37B C(0)OR 37B NHC(0)NH 2 , NHC(0)NHR 37B , NHC(0)N(R 37B ) 2 , NR 37B C(0)NHR 37B , NR 37B C(0)N(R 37B ) 2 , C(0)NH 2 , C(0)NHR 37B , C(0)N(R 37B ) 2 , C(0)NHOH, C(0)NHOR 37B , C(0)NHS0 2 R 37B , C(0)NR 37B S0 2 R 37B , S0 2 NH 2 , S0 2 NHR 37B , S0 2 N(R 37B ) 2 , C(0)H, C(0)OH, C(N)NH 2 , C(N)NHR 37B , C(N)N(R 37B ) 2 , CNOH, CNOCH 3 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , N
• R 37B is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;
• Z 3 is R 38 , R 39 or R 40 ;
• R 38 is phenyl, which is unfused or fused with benzene, heteroarene or R 38A ;
• R 38A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 39 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 39A ;
• R 39A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R >40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 40A ;
• R 40A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 42 wherein the moieties represented by R 42 are independently substituted with one or two or three or four of independently selected R 50 , OR 50 , SR 50 , S(0)R 50 , S0 2 R 50 , C(0)R 50 , CO(0)R 50 , OC(0)R 50 , OC(0)OR 50 , NH 2 , NHR 50 , N(R 50 ) 2 , NHC(0)R 50 , NR 50 C(O)R 50 , NHS(0) 2 R 50 , NR 50 S(O) 2 R 50 , NHC(0)OR 5 °, NR 50 C(O)OR 50 , NHC(0)NH 2 , NHC(0)NHR 50 ,
• R 50 is R 51 , R 52 , R 53 or R 54 ;
• R 51 is phenyl, which is unfused or fused with benzene, heteroarene or R 51A ;
• R 51A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 52 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 52A ;
• R 52A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 53 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 53A ;
• R 53A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 54 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 55 , OR 55 , SR 55 , S(0)R 55 , S0 2 R 55 , C(0)R 55 , CO(0)R 55 , OC(0)R 55 , OC(0)OR 55 , NH 2 , NHR 55 , N(R 55 ) 2 , NHC(0)R 55 , NR 55 C(0)R 55 ,
• R 55 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
• R 26 is further unsubstituted or further substituted and each foregoing cyclic moiety are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R 57A , R 57 , OR 57 , SR 57 , S(0)R 57 , S0 2 R 57 , C(0)R 57 , CO(0)R 57 , OC(0)R 57 , OC(0)OR 57 , NH 2 , NHR 57 , N(R 57 ) 2 , NHC(0)R 57 , NR 57 C(0)R 57 , NHS(0) 2 R 57 , NR 57 S(0) 2 R 57 , NHC(0)OR 57 , NR 57 C(0)OR 57 , NHC(0)NH 2 , NHC(0)NHR 57 , NHC(0)N(R 57 ) 2 , NR 57 C(0)NHR 57 , NR 57 C(0)
• R 57A is spirocyclyl
• R 57 is R 58 , R 59 , R 60 or R 61 ;
• R 58 is phenyl, which is unfused or fused with benzene, heteroarene or R 58A ;
• R 58A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 59 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 59A ;
• R 59A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 60A ;
• R 60A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 62 , OR 62 , SR 62 , S(0)R 62 , S0 2 R 62 , C(0)R 62 , CO(0)R 62 , OC(0)R 62 , OC(0)OR 62 , NH 2 , NHR 62 , N(R 62 ) 2 , NHC(0)R 62 , NR 62 C(0)R 62 ,
• R 62 is R 63 , R 64 , R 65 or R 66 ;
• R 63 is phenyl, which is unfused or fused with benzene, heteroarene or R 63A ;
• R 63A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 64 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 64A ;
• R 64A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 65 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 65A ;
• R 65A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 66 is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 67 , OR 67 , SR 67 , S(0)R 67 , S0 2 R 67 , C(0)R 67 , CO(0)R 67 , OC(0)R 67 , OC(0)OR 67 , NH 2 , NHR 67 , N(R 67 ) 2 , NHC(0)R 67 , NR 67 C(0)R 67 , NHS(0) 2 R 67 , NR 67 S(0) 2 R 67 , NHC(0)OR 67 , NR 67 C(0)OR 67 , NHC(0)NH 2 , NHC(0)NHR 67 , NHC(0)N(R 67 ) 2 , NR 67 C(0)NHR 67 , NR 67 C(0)N(R 67 ) 2 , C(0)NH 2 , C(0)NHR 67 , C(0)N
• RR 67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, pphhenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
• R 57A , R 58 , R 59 , R 60 , R 63 , R 64 , R 65 , and R 67 are unsubstituted or substituted with one or two or three or four of independently selected R 68 , OR 68 , SR 68 , S(0)R 68 , S0 2 R 68 , C(0)R 68 , CO(0)R 68 , OC(0)R 68 , OC(0)OR 68 , NH 2 , NHR 68 , N(R 68 ) 2 , NHC(0)R 68 , NR 68 C(0)R 68 , NHS(0) 2 R 68 , NR 68 S(0) 2 R 68 , NHC(0)OR 68 ,
• NR 68 C(0)OR 68 NHC(0)NH 2 , NHC(0)NHR 68 , NHC(0)N(R 68 ) 2 , NR 68 C(0)NHR 68 ,
• R 68 is R 69 , R 70 , R 71 or R 72 ;
• R 69 is phenyl, which is unfused or fused with benzene, heteroarene or R 69A ;
• R 69A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 70 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 70A ;
• R 70A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 71A ;
• R 71A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 72 is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 73 , OR 73 , SR 73 , S(0)R 73 , S0 2 R 73 , C(0)R 73 , CO(0)R 73 , OC(0)R 73 , OC(0)OR 73 , NH 2 , NHR 73 , N(R 73 ) 2 , NHC(0)R 73 , NR 73 C(0)R 73 ,
• R 73 is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
• the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH 2 , C(0)NH 2 , C(0)NHOH, S0 2 NH 2 , CF 3 , CF 2 CF 3 , C(0)H, C(0)OH, C(N)NH 2 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, CI, Br or I.
• Still another embodiment pertains to a compound of Formula I or Formula II, wherein A 1 is C(A 2 ); and A 2 is H.
• Still another embodiment pertains to a compound of Formula I or Formula II, wherein A 1 is C(A 2 ) or N; A 2 is H; and B 1 is NHR 1 .
• Still another embodiment pertains to a compound of Formula I or Formula II, wherein A 1 is C(A 2 ) or N; A 2 is H; B 1 is NHR 1 ; and D 1 is H.
• Still another embodiment pertains to a compound of Formula I or Formula II, wherein
• a 1 is C(A 2 ) or N; A 2 is H; B 1 is NHR 1 ; D 1 is H; and E 1 is H.
• Still another embodiment pertains to a compound of Formula I or Formula II, wherein A 1 is C(A 2 ) or N; A 2 is H; B 1 is NHR 1 ; D 1 is H; E 1 is H; and Y 1 is N0 2.
• Still another embodiment pertains to compounds having Formula I, which are 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-
• Still another embodiment pertains to 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- ⁇ [2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl ⁇ piperazin-l-yl)-N-( ⁇ 3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4- (4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N-( ⁇ 4- [(4- morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl ⁇ sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- ⁇ [2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl ⁇ piperazin-l-yl)-N-[(3-nitro-4- ⁇ [(3R)-l-(oxetan-3-yl)pyrrolidin-3-yl]amino ⁇ phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to Trans-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl ⁇ piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(3- nitro-4- ⁇ [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino ⁇ phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl ⁇ piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(3- nitro-4- ⁇ [(3S)-tetrahydro-2H-pyran-3-ylmethyl]amino ⁇ phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-2- [(6-fluoro- lH-indol-4-yl)oxy] -N- [(3 - nitro-4- ⁇ [3-(3-oxopiperazin-l-yl)propyl]amino ⁇ phenyl)sulfonyl]benzamide; and
• Still another embodiment pertains to 2-(2-chlorophenoxy)-4-(4- ⁇ [2-(4-chlorophenyl)-
• Still another embodiment pertains to 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-2-(3 ,4-dichlorophenoxy)-N-( ⁇ 4- [( 1 - methylpiperidin-4-yl)amino]-3-nitrophenyl ⁇ sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-isopropylpiperidin-4- yl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 4-(4-((4'-chloro-l,l'-biphenyl-2- yl)methyl)piperazin-l-yl)-2-(2-(2-(dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro- 2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 4-(4-((4'-chloro-l,l'-biphenyl-2- yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-6-yl)oxy)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 4-(4-((4'-chloro-l,l'-biphenyl-2- yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Still another embodiment pertains to 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl)methyl)piperazin- 1 -yl)-2-((2-methyl- lH-indol-5-yl)oxy)-N-((4-(( 1 - methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
• Another embodiment pertains to a composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia,
• colorectal cancer esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound of Formula (I).
• Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of Formula (I).
• Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
• Variable moieties herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
• variable moiety herein may be the same or different as another specific embodiment having the same identifier.
• alkenyl as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond.
• C x -C y alkyl means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond containing x to y carbon atoms.
• C2-C4 alkenyl means an alkenyl group containing 2-4 carbon atoms.
• alkenyl include, but are not limited to buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4- pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
• alkenylene means a divalent group derived from a straight or branched chain hydrocarbon of 2 to 4 carbon atoms and contains at least one carbon-carbon double bond.
• C x -C y alkylene means a divalent group derived from a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing x to y carbon atoms.
• alkyl as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms.
• Cx-C y alkyl means a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms.
• C2-C1 0 alkyl means a straight or branched chain, saturated hydrocarbon containing 2 to 10 carbon atoms.
• alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec -butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3- methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
• alkylene means a divalent group derived from a straight or branched, saturated hydrocarbon chain of 1 to 10 carbon atoms, for example, of 1 to 4 carbon atoms.
• Cx-C y alkylene means a divalent group derived from a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms.
• C 2 -C6 alkylene means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms.
• alkylene examples include, but are not limited to, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and -CH 2 CH(CH 3 )CH 2 -.
• alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
• C x -C y alkynyl means a straight or branched chain hydrocarbon group containing from x to y carbon atoms.
• Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
• alkynylene means a divalent radical derived from a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
• aryl as used herein, means phenyl.
• cyclic moiety means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkylene, cycloalkene, cycloalkenyl, cycloalkenylene, cycloalkyne, cycloalkynyl, cycloalkynylene, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and spiroalkyl.
• cycloalkylene or cycloalkyl or “cycloalkane” as used herein, means a monocyclic or bridged hydrocarbon ring system.
• the monocyclic cycloalkyl is a carbocyclic ring system containing three to eight carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
• the monocyclic ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non- adjacent carbon atoms of the ring system.
• Non- limiting examples of such bridged cycloalkyl ring systems include bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tricyclo[3.3.1.0 3 ' 7 ]nonane (octahydro-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.1 3 ' 7 ]decane
• the monocyclic and bridged cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system.
• cycloalkenylene or "cycloalkenyl” or “cycloalkene” as used herein, means a monocyclic or a bridged hydrocarbon ring system.
• the monocyclic cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms and zero heteroatoms.
• the four-membered ring systems have one double bond, the five-or six-membered ring systems have one or two double bonds, and the seven- or eight-membered ring systems have one, two, or three double bonds.
• monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
• the monocyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
• Representative examples of the bicyclic cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene.
• the monocyclic and bicyclic cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems.
• cycloalkyne or "cycloalkynyl,” or “cycloalkynylene,” as used herein, means a monocyclic or a bridged hydrocarbon ring system.
• the monocyclic cycloalkynyl has eight or more carbon atoms, zero heteroatoms, and one or more triple bonds.
• the monocyclic cycloalkynyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
• the monocyclic and bridged cycloalkynyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems.
• heteroaryl or “heteroarylene,” as used herein, means a five-membered or six-membered aromatic ring having at least one carbon atom and one or more than one independently selected nitrogen, oxygen or sulfur atom.
• the heteroarenes of this invention are connected through any adjacent atoms in the ring, provided that proper valences are maintained.
• heteroaryl include, but are not limited to, furanyl (including, but not limited thereto, furan-2-yl), imidazolyl (including, but not limited thereto, lH-imidazol-l-yl), isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl (e.g.
• pyridin-4-yl pyridin-2-yl, pyridin-3-yl
• pyridazinyl pyrimidinyl
• pyrazinyl pyrazolyl
• pyrrolyl tetrazolyl
• thiadiazolyl thiazolyl
• thienyl including, but not limited thereto, thien-2- yl, thien-3-yl
• triazolyl including, but not limited thereto, thien-2- yl, thien-3-yl
• heterocycloalkane or “heterocycloalkyl,” or “heterocycloalkylene,” as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and zero double bonds.
• heterocycloalkane are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings.
• the nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized.
• heterocycloalkane groups include, but are not limited to, Representative examples of heterocycloalkane groups include, but are not limited to, morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, dioxolanyl, tetrahydrofuranyl, thiomorpholinyl, dioxanyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxetanyl, piperazinyl, imidazolidinyl, azetidine, azepanyl, aziridinyl, diazepanyl, dithiolanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, oxadiazolidinyl, oxazolidinyl, pyrazolidinyl, tetrahydrothienyl, thiadiazolidinyl, thiazolidinyl,
• heterocycloalkene or “heterocycloalkenyl,” or “heterocycloalkenylene,” as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group
• the monocyclic and bridged heterocycloalkene are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings.
• the nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized.
• heterocycloalkene groups include, but are not limited to, tetrahydrooxocinyl, 1,4,5,6-tetrahydropyridazinyl, 1,2,3,6- tetrahydropyridinyl, dihydropyranyl, imidazolinyl, isothiazolinyl, oxadiazolinyl, isoxazolinyl, oxazolinyl, pyranyl, pyrazolinyl, pyrrolinyl, thiadiazolinyl, thiazolinyl, and thiopyranyl.
• phenylene as used herein, means a divalent radical formed by removal of a hydrogen atom from phenyl.
• spiroalkyl means alkylene, both ends of which are attached to the same carbon atom and is exemplified by C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl, Cs-spiroalkyl, C6-spiroalkyl, C7-spiroalkyl, Cs-spiroalkyl, C9-spiroalkyl and the like.
• spiroheteroalkyl means spiroalkyl having one or two CH 2 moieties replaced with independently selected O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH and one or two CH moieties unreplaced or replaced with N.
• spiroheteroalkenyl means spiroalkenyl having one or two CH 2 moieties replaced with independently selected O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH and one or two CH moieties unreplaced or replaced with N and also means spiroalkenyl having one or two CH 2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH and one or two CH moieties replaced with N.
• spirocyclo means two substituents on the same carbon atom, that, together with the carbon atom to which they are attached, form a cycloalkane, heterocycloalkane, cycloalkene, or heterocycloalkene ring.
• C 2 -C5-spiroalkyl means C 2 -spiroalkyl, C 3 -spiroalkyl, C4-spiroalkyl, and Cs-spiroalkyl.
• C 2 -spiroalkyl means eth-l,2-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
• C 3 -spiroalkyl means prop-l,3-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
• C4-spiroalkyl means but-l,4-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
• Cs-spiroalkyl as used herein, means pent-l,5-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
• C6-spiroalkyl means hex-l,6-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
• NH protecting group means trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl,
• ortho-bromobenzyloxycarbonyl chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyl-oxycarbonyl,
• C(0)OH protecting group means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para- methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl 2-tetrahydrofuranyl, 2,2,2-trichloro- ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl
• OH or SH protecting group means benzyloxycarbonyl, 4- nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl,
• Geometric isomers may exist in the present compounds.
• Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond and the term “Z” represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules.
• the compounds of this invention may also exist as a mixture of "E” and "Z” isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration.
• the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system.
• Two substituents around a single ring within an adamantane ring system are designated as being of Z or E relative configuation.
• Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R” and “S” are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10.
• Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one
• this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
• prodrug-forming moieties may have attached thereto prodrug-forming moieties.
• the prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed hydroxyl, amino or carboxylic acid in vivo.
• Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance.
• An example of a compound with a prodrug-forming moiety is [3-chloro-5-(5-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-2- ⁇ [( ⁇ 3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl ⁇ sulfonyl)amino]carbonyl ⁇ phenoxy)-2-iminopyridin-l(2H)-yl]methyl dihydrogen phosphate (EXAMPLE 397), which is a prodrug of 2-[(6-amino-5-chloropyridin- 3-yl)oxy]-4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl ⁇ piperazin-l-yl)-
• Compounds of the invention can exist in isotope-labeled or isotope-enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature.
• Isotopes can be radioactive or non-radioactive isotopes.
• Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur,
• 18 32 fluorine, chlorine, and iodine include, but are not limited to, H, H, C, C, N, O, P, 35 S, 18 F, 36 C1, and 125 I.
• Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
• the isotope-labeled compounds contain deuterium ( 2 H), tritium ( 3 H) or 14 C isotopes.
• Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope- labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope- labeled reagent for a non-labeled reagent.
• compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D 2 SO 4 /D 2 O.
• a deuteric acid such as D 2 SO 4 /D 2 O.
• the isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of Bcl-2 inhibitors in binding assays.
• Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. /. Pharm. Sci. 64, 3, 367-391 (1975)).
• Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al.,
• non-radio active isotope containing drugs such as deuterated drugs
• “heavy drugs,” can be used for the treatment of diseases and conditions related to Bcl-2 activity.
• Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment.
• Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol .
• Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y.
• Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
• Prodrugs are derivatives of an active drug designed to ameliorate some identified, undesirable physical or biological property.
• the physical properties are usually solubility (too much or not enough lipid or aqueous solubility) or stability related, while problematic biological properties include too rapid metabolism or poor bioavailability which itself may be related to a physicochemical property.
• Prodrugs are usually prepared by: a) formation of ester, hemi esters, carbonate esters, nitrate esters, amides, hydroxamic acids, carbamates, imines, Mannich bases, phosphates, phosphate esters, and enamines of the active drug, b) functionalizing the drug with azo, glycoside, peptide, and ether functional groups, c) use of aminals, hemi-aminals, polymers, salts, complexes, phosphoramides, acetals, hemiacetals, and ketal forms of the drug.
• Esters can be prepared from substrates of formula (I) containing either a hydroxyl group or a carboxy group by general methods known to persons skilled in the art. The typical reactions of these compounds are substitutions replacing one of the heteroatoms by another atom, for example:
• Amides can be prepared from substrates of formula (I) containing either an amino group or a carboxy group in similar fashion. Esters can also react with amines or ammonia to form amides.
• Another way to make amides from compounds of formula (I) is to heat carboxylic acids and amines together.
• R and R' are independently substrates of formula (I), alkyl or hydrogen.
• Suitable groups for for A 1 , B 1 , D 1 , E 1 , Y 1 , L 1 , Z 1A , Z 2A , Z 1 , Z 2 , and Z 3 in compounds of Formula (I) are independently selected.
• the described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention.
• any of A 1 , B 1 , D 1 , E 1 , Y 1 , L 1 , Z 1 A , Z 2A , Z 1 , Z 2 , and Z 3 can be combined with embodiments defined for any other of A 1 , B 1 , D 1 , E 1 , Y 1 , L 1 , Z 1A , Z 2A , Z 1 , Z 2 , and Z 3 .
• a 1 is N or C(A 2 );
• a 2 is H, R 1 , OR 1 , SR 1 , NHR 1 , NCR 1 )!, C(0)NHR 1 , CCCONCR 1 )!, NHC(0)R 1 , NR ⁇ CCOR 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 ,
• B 1 is H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R 1 , C(0)OR ⁇ OC(0)R ⁇ NHR 1 , N(R ] ) 2 , C(0)NHR 1 , C ⁇ NCR ⁇ z, NHC(0)R 1 , NR ⁇ CCOR 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 ,
• D 1 is H, R 1 , OR 1 , SR 1 , 0C(0)R 1 , NHR 1 , NCR 1 ) ! , C(0)N(R 1 ) 2 , NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)0R 1 , NR 1 C(0)0R 1 ,
• E 1 is H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R 1 , C(0)0R 1 , 0C(0)R 1 , NHR 1 , N(R ] ) 2 ,
• Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 , C(0)R 17 , C(0)OR 17 , SR 17 , S0 2 R 17 , NH 2 , NHR 17 , N(R 17 ) 2 , NHC(0)R 17 , C(0)NH 2 ,
• E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
• a 2 , B 1 , and D 1 are independently selected H, R 1 , OR 1 , SR 1 ,
• NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 ,
• Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• a 2 , D 1 , and E 1 are independently selected H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇
• a 2 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• D 1 , E 1 , and Y 1 are independently selected H, R 1 , OR 1 , SR 1 , S(0)R ⁇ S0 2 R ⁇ C(0)R ⁇ NHC(0)R 1 , NR 1 C(0)R 1 , NHC(0)OR 1 , NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR ⁇ NCR ⁇ z, S0 2 NH 2 , S0 2 NHR ⁇ SOzNCR 1 ⁇ , NHS0 2 R ⁇ NR ⁇ OzR 1 , NHS0 2 NHR ⁇ NHSOzNCR ⁇ z, NR ⁇ OzNHR 1 , NR ⁇ OzNCR 1 ⁇ , C(0)NHNOH, C(0)NHNOR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
• a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
• B 1 , E 1 , and Y 1 are independently selected H, R 1 , OR 1 , SR 1 ,
• NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 ,
• C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
• R 1 is R 2 , R 3 , R 4 or R 5 ;
• R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
• R is phenyl, which is unfused or fused with benzene, heteroarene or R ;
• R is cycloalkane or heterocycloalkane;
• R 3 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 3A ;
• R 3A is cycloalkane or heterocycloalkane;
• R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R 4A ;
• R 4A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , NHC(0)NH 2 , NHC(0)NHR 7 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 1 , OH, (O), C(0)OH
• R 6 is C 2 -C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N 3 , CN, CF 3 , CF 2 CF 3 , F, CI, Br, I, NH 2 , NH(CH 3 ) or N(CH 3 ) 2 ;
• R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
• R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
• R 7 is R 8 , R 9 , R 10 or R n ;
• R 8 is phenyl, which is unfused or fused with benzene, heteroarene or R 8A ;
• R 8A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 9 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 9A ;
• R 9A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 10A ;
• R 10A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 ,
• R 12 is R 13 , R 14 , R 15 or R 16 ;
• R 13 is phenyl, which is unfused or fused with benzene, heteroarene or R 13A ;
• R 13A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 14 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 14A ;
• R 14A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R 15A ;
• R 15A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 16 is alkyl, alkenyl or alkynyl
• R 17 is R 18 , R 19 , R 20 or R 21 ;
• R 18 is phenyl, which is unfused or fused with benzene, heteroarene or R 18A ;
• R 18A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 19 is heteroaryl, which is unfused or fused with benzene, heteroarene or R 19A ;
• R 19A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 20A ;
• R 20A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 ,
• R 22 is R 23 , R 24 or R 25 ;
• R 23 is phenyl, which is unfused or fused with benzene, heteroarene or R 23A ;
• R 23A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 24 is heteroarene, which is unfused or fused with benzene, heteroarene or R 24A ;
• R 24A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R 25A ;
• R 25A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• Z 1 is R 26 or R 27 ;
• Z 2 is R 28 , R 29 or R 30 ;
• Z 1A and Z 2A are both absent or are taken together to form CH 2 , CH 2 CH 2 or Z 12A ;
• Z 12A is C 2 -C6-alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S, S(O) or S0 2 ;
• L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
• R is phenylene, which is unfused or fused with benzene or heteroarene or R ;
• R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 27 is heteroarylene, which is unfused or fused with benzene or heteroarene or R 27A ;
• R 27A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene
• R 28 is phenylene, which is unfused or fused with benzene, heteroarene or R 28A ;
• R 28A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
• R 29 is heteroarylene, which is unfused or fused with benzene or heteroarene or R 29A ;
• R 29A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ;

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Hydrogenated Pyridines (AREA)
• Pyridine Compounds (AREA)
• Pyrane Compounds (AREA)
• Indole Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (19)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42463423

Family Applications (1)

Country Status (30)

Cited By (30)

Families Citing this family (20)

Citations (28)

Family Cites Families (39)

• 2009
  • 2009-12-04 US US12/631,367 patent/US20100160322A1/en not_active Abandoned
• 2010
  • 2010-06-01 PH PH1/2012/501071A patent/PH12012501071A1/en unknown
  • 2010-06-01 ES ES10722500.5T patent/ES2487617T3/es active Active
  • 2010-06-01 CN CN201610801580.3A patent/CN106397418A/zh active Pending
  • 2010-06-01 DK DK10722500.5T patent/DK2507211T3/da active
  • 2010-06-01 MX MX2012006391A patent/MX2012006391A/es unknown
  • 2010-06-01 BR BR112012012918A patent/BR112012012918A8/pt not_active Application Discontinuation
  • 2010-06-01 JP JP2012541997A patent/JP5589090B2/ja active Active
  • 2010-06-01 SI SI201030743T patent/SI2507211T1/sl unknown
  • 2010-06-01 SG SG2012041018A patent/SG181506A1/en unknown
  • 2010-06-01 NZ NZ600084A patent/NZ600084A/en not_active IP Right Cessation
  • 2010-06-01 PL PL10722500T patent/PL2507211T3/pl unknown
  • 2010-06-01 CA CA2781521A patent/CA2781521A1/en not_active Abandoned
  • 2010-06-01 PT PT107225005T patent/PT2507211E/pt unknown
  • 2010-06-01 EP EP10722500.5A patent/EP2507211B1/en active Active
  • 2010-06-01 RU RU2012127790/04A patent/RU2535203C2/ru active
  • 2010-06-01 MY MYPI2012700318A patent/MY161340A/en unknown
  • 2010-06-01 UA UAA201208181A patent/UA106403C2/ru unknown
  • 2010-06-01 PE PE2012000765A patent/PE20121496A1/es active IP Right Grant
  • 2010-06-01 CN CN201080065339XA patent/CN103097352A/zh active Pending
  • 2010-06-01 AU AU2010326727A patent/AU2010326727B2/en not_active Ceased
  • 2010-06-01 WO PCT/US2010/036844 patent/WO2011068560A1/en not_active Ceased
  • 2010-06-02 AR ARP100101936A patent/AR076946A1/es unknown
  • 2010-06-02 TW TW99117829A patent/TWI473801B/zh not_active IP Right Cessation
• 2012
  • 2012-05-24 IL IL219991A patent/IL219991A/en active IP Right Grant
  • 2012-05-31 CL CL2012001421A patent/CL2012001421A1/es unknown
  • 2012-06-01 DO DO2012000154A patent/DOP2012000154A/es unknown
  • 2012-06-07 CO CO12096369A patent/CO6571908A2/es active IP Right Grant
  • 2012-06-25 CR CR20120347A patent/CR20120347A/es unknown
  • 2012-07-03 EC ECSP12012020 patent/ECSP12012020A/es unknown
• 2013
  • 2013-07-26 US US13/952,278 patent/US8952157B2/en active Active
• 2014
  • 2014-08-27 CY CY20141100684T patent/CY1115502T1/el unknown
  • 2014-12-23 US US14/582,144 patent/US9303025B2/en active Active
• 2016
  • 2016-02-19 US US15/048,901 patent/US20160304451A1/en not_active Abandoned
• 2017
  • 2017-10-13 US US15/783,993 patent/US20180251426A1/en not_active Abandoned

Patent Citations (29)

Non-Patent Citations (21)

Also Published As

Similar Documents

Legal Events